Abbott Laboratories $ABT Shares Acquired by Allianz SE

Allianz SE boosted its holdings in Abbott Laboratories (NYSE:ABT) by 20.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 109,724 shares of the healthcare product maker’s stock after buying an additional 18,281 shares during the quarter. Allianz SE’s holdings in Abbott Laboratories were worth $14,924,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC lifted its stake in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after buying an additional 4,755 shares in the last quarter. PAX Financial Group LLC lifted its position in shares of Abbott Laboratories by 27.3% in the 1st quarter. PAX Financial Group LLC now owns 3,320 shares of the healthcare product maker’s stock valued at $440,000 after acquiring an additional 712 shares in the last quarter. Parcion Private Wealth LLC boosted its stake in Abbott Laboratories by 3.4% in the 1st quarter. Parcion Private Wealth LLC now owns 70,491 shares of the healthcare product maker’s stock worth $9,351,000 after purchasing an additional 2,304 shares during the period. Guardian Wealth Advisors LLC grew its position in Abbott Laboratories by 4.1% during the 1st quarter. Guardian Wealth Advisors LLC now owns 6,431 shares of the healthcare product maker’s stock worth $853,000 after purchasing an additional 256 shares in the last quarter. Finally, Cullen Frost Bankers Inc. raised its stake in Abbott Laboratories by 0.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 169,447 shares of the healthcare product maker’s stock valued at $22,477,000 after purchasing an additional 1,534 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

NYSE:ABT opened at $128.83 on Thursday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The company has a 50-day moving average of $130.50 and a 200-day moving average of $131.36. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a market capitalization of $224.02 billion, a price-to-earnings ratio of 16.14, a PEG ratio of 2.36 and a beta of 0.68.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.30. The firm had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.78%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s payout ratio is currently 29.57%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on ABT shares. Daiwa Capital Markets lifted their price target on Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a report on Tuesday, October 21st. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Mizuho raised their price target on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, October 14th. Wells Fargo & Company upped their price objective on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research note on Thursday, October 16th. Finally, Barclays lifted their target price on shares of Abbott Laboratories from $159.00 to $162.00 and gave the company an “overweight” rating in a research note on Friday, October 17th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average price target of $147.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.